ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ALZN Alzamend Neuro Inc

0.49
-0.0769 (-13.57%)
Jun 14 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0769 -13.57% 0.49 23:00:03
Open Price Low Price High Price Close Price Previous Close
0.508 0.4411 0.5088 0.4545 0.5669
more quote information »

Recent News

Date Time Source Heading
6/11/202415:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
6/03/202415:30EDGAR2Form S-1 - General form for registration of securities under..
5/31/202415:59EDGAR2Form DEF 14A - Other definitive proxy statements
5/22/202415:30EDGAR2Form 8-K - Current report
5/22/202407:00BWAlzamend Neuro Announces Favorable Decision from Nasdaq..
5/16/202415:30EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
5/14/202407:00BWAlzamend Neuro Announces Initial Closing of Private..
5/13/202415:30EDGAR2Form 8-K - Current report
5/10/202416:06EDGAR2Form PRE 14A - Other preliminary proxy statements
5/10/202415:30EDGAR2Form 8-K/A - Current report: [Amend]
5/10/202405:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
5/09/202415:30EDGAR2Form 8-K - Current report
5/09/202415:20EDGAR2Form 8-K - Current report
5/09/202407:00BWAlzamend Neuro Announces Agreement for Registered Direct..
5/07/202415:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
5/07/202415:30EDGAR2Form 8-K - Current report
5/07/202407:00BWAlzamend Neuro Announces Termination of At-the-Market Equity..
3/07/202415:30EDGAR2Form 8-K - Current report
2/02/202415:30EDGAR2Form 8-K - Current report
1/05/202415:30EDGAR2Form 8-K - Current report
12/15/202315:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202307:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/20/202307:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/16/202315:30EDGAR2Form 8-K - Current report
11/16/202307:00BWAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
11/13/202307:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
10/30/202315:30EDGAR2Form 8-K - Current report
10/30/202307:00BWAlzamend Neuro Announces Reverse Stock Split
10/23/202307:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
10/02/202307:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
9/29/202315:30EDGAR2Form 8-K - Current report
9/26/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/22/202315:30EDGAR2Form 8-K - Current report
9/22/202307:00BWAlzamend Neuro Granted Extension by Nasdaq Panel to Regain..
9/13/202316:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/08/202316:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
9/08/202316:00EDGAR2Form 8-K - Current report
9/01/202315:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
8/30/202307:00BWAlzamend Neuro Submits IND Application for Phase IIA..
8/24/202315:30EDGAR2Form DEF 14A - Other definitive proxy statements
8/16/202315:30EDGAR2Form 8-K - Current report
8/10/202315:30EDGAR2Form PRE 14A - Other preliminary proxy statements
8/07/202315:30EDGAR2Form 8-K - Current report
8/02/202315:31EDGAR2Form S-3 - Registration statement under Securities Act of..
7/27/202315:56EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
6/22/202307:00BWAlzamend Neuro Announces Positive Phase IIA Clinical Trial..

Your Recent History

Delayed Upgrade Clock